Neuraxpharm Arzneimittel GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neuraxpharm Arzneimittel GmbH
Neuraxpharm and Panaxia have become the first companies in the world to market medical cannabis extract, under the joint brand Naxiva-Panaxol, for vaporization in Germany. Under the agreement, the extracts will be manufactured by Panaxia and marketed in Germany by Neuraxpharm.
Neuraxpharm has appoints Viatris’ head of finance in Germany as its new commercial central region officer and country manager to strengthen its position in the German market, while Stada has hired a new head of consumer health in Germany. Meanwhile, the AAM has made multiple key appointments and Hyloris, Siegfried and Mayne Pharma have made top-level additions.
CNS specialist Neuraxpharm has announced expanding its strategic collaboration with Panaxia Labs Israel for advanced medical cannabis-based pharmaceutical products to Poland, after Germany and France. The companies expect sale of the cannabis portfolio to commence in the first half of 2022.
For the second time in as many months, Neuraxpharm has looked to Viatris to recruit a top executive to help lead the CNS specialist’s continuing expansion in Europe.
- Generic Drugs
- OTC, Consumer